NCT06315400

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Double-blind, Multicenter, Randomized, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of Ingavirin®, 60 mg Capsules in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Children Aged 13-17 Years.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 13 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, capsules, 60 mg, in the treatment of influenza or other acute respiratory infections in children from 13 to 17 years compared with placebo.

Conditions

• Influenza, Human
• Acute Respiratory Infection
• Common Cold

Interventions

Type	Name	Description
DRUG	Ingavirin®	60 mg/day for 5 days
DRUG	Placebo	1 capsule/day for 5 days

Timeline

• Start date: 2023-12-19
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2024-03-18
• Last updated: 2024-04-01

Locations

3 sites across 1 country: Russia